Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may represent a promising development for weight management . Preliminary patient https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026